1
|
Vander Heiden MG and DeBerardinis RJ:
Understanding the intersections between metabolism and cancer
biology. Cell. 168:657–669. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Liberti MV and Locasale JW: The Warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Schwartz L, Supuran CT and Alfarouk KO:
The Warburg effect and the hallmarks of cancer. Anticancer Agents
Med Chem. 17:164–170. 2017. View Article : Google Scholar
|
4
|
Yu L, Lu M, Jia D, Ma J, Ben-Jacob E,
Levine H, Kaipparettu BA and Onuchic JN: Modeling the genetic
regulation of cancer metabolism: Interplay between glycolysis and
oxidative phosphorylation. Cancer Res. 77:1564–1574. 2017.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Jing X, Yang F, Shao C, Wei K, Xie M, Shen
H and Shu Y: Role of hypoxia in cancer therapy by regulating the
tumor microenvironment. Mol Cancer. 18:1572019. View Article : Google Scholar : PubMed/NCBI
|
6
|
Zhang Y, Zhang H, Wang M, Schmid T, Xin Z,
Kozhuharova L, Yu WK, Huang Y, Cai F and Biskup E: Hypoxia in
breast cancer-scientific translation to therapeutic and diagnostic
clinical applications. Front Oncol. 11:6522662021. View Article : Google Scholar : PubMed/NCBI
|
7
|
Miranda E, Nordgren IK, Male AL, Lawrence
CE, Hoakwie F, Cuda F, Court W, Fox KR, Townsend PA, Packham GK, et
al: A cyclic peptide inhibitor of HIF-1 heterodimerization that
inhibits hypoxia signaling in cancer cells. J Am Chem Soc.
135:10418–10425. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Burslem GM, Kyle HF, Nelson A, Edwards TA
and Wilson AJ: Hypoxia inducible factor (HIF) as a model for
studying inhibition of protein-protein interactions. Chem Sci.
8:4188–4202. 2017. View Article : Google Scholar : PubMed/NCBI
|
9
|
Nagao A, Kobayashi M, Koyasu S, Chow CCT
and Harada H: HIF-1-dependent reprogramming of glucose metabolic
pathway of cancer cells and its therapeutic significance. Int J Mol
Sci. 20:2382019. View Article : Google Scholar :
|
10
|
Saponaro C, Malfettone A, Ranieri G, Danza
K, Simone G, Paradiso A and Mangia A: VEGF, HIF-1α expression and
MVD as an angiogenic network in familial breast cancer. PLoS One.
8:e530702013. View Article : Google Scholar
|
11
|
Shen LF, Zhou SH and Yu Q: Relationships
between expression of glucose transporter protein-1 and hypoxia
inducible factor-1α, prognosis and 18F-FDG uptake in
laryngeal and hypopharyngeal carcinomas. Transl Cancer Res.
9:2824–2837. 2020. View Article : Google Scholar : PubMed/NCBI
|
12
|
Semenza GL: HIF-1 mediates metabolic
responses to intratumoral hypoxia and oncogenic mutations. J Clin
Invest. 123:3664–3671. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
He G, Yi J, Bo Z and Wu G: The effect of
HIF-1α on glucose metabolism, growth and apoptosis of pancreatic
cancerous cells. Asia Pac J Clin Nutr. 23:174–180. 2014.
|
14
|
Goodwin J, Choi H, Hsieh MH, Neugent ML,
Ahn JM, Hayenga HN, Singh PK, Shackelford DB, Lee IK, Shulaev V, et
al: Targeting hypoxia-inducible factor-1α/pyruvate dehydrogenase
kinase 1 axis by dichloroacetate suppresses bleomycin-induced
pulmonary fibrosis. Am J Respir Cell Mol Biol. 58:216–231. 2018.
View Article : Google Scholar :
|
15
|
Kierans SJ and Taylor CT: Regulation of
glycolysis by the hypoxia-inducible factor (HIF): Implications for
cellular physiology. J Physiol. 599:23–37. 2021. View Article : Google Scholar
|
16
|
Samec M, Liskova A, Koklesova L, Mersakova
S, Strnadel J, Kajo K, Pec M, Zhai K, Smejkal K, Mirzaei S, et al:
Flavonoids targeting HIF-1: Implications on cancer metabolism.
Cancers (Basel). 13:1302021. View Article : Google Scholar
|
17
|
Condelli V, Crispo F, Pietrafesa M,
Lettini G, Matassa DS, Esposito F, Landriscina M and Maddalena F:
HSP90 molecular chaperones, metabolic rewiring, and epigenetics:
Impact on tumor progression and perspective for anticancer therapy.
Cells. 8:5322019. View Article : Google Scholar :
|
18
|
Maddalena F, Simeon V, Vita G, Bochicchio
A, Possidente L, Sisinni L, Lettini G, Condelli V, Matassa DS, Li
Bergolis V, et al: TRAP1 protein signature predicts outcome in
human metastatic colorectal carcinoma. Oncotarget. 8:21229–21240.
2017. View Article : Google Scholar : PubMed/NCBI
|
19
|
Amoroso MR, Matassa DS, Sisinni L, Lettini
G, Landriscina M and Esposito F: TRAP1 revisited: Novel
localizations and functions of a 'next-generation' biomarker
(review). Int J Oncol. 45:969–977. 2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Masgras I, Sanchez-Martin C, Colombo G and
Rasola A: The chaperone TRAP1 as a modulator of the mitochondrial
adaptations in cancer cells. Front Oncol. 7:582017. View Article : Google Scholar : PubMed/NCBI
|
21
|
Avolio R, Matassa DS, Criscuolo D,
Landriscina M and Esposito F: Modulation of mitochondrial metabolic
reprogramming and oxidative stress to overcome Chemoresistance in
Cancer. Biomolecules. 10:1352020. View Article : Google Scholar :
|
22
|
Matassa DS, Agliarulo I, Avolio R,
Landriscina M and Esposito F: TRAP1 regulation of cancer
metabolism: Dual role as oncogene or tumor suppressor. Genes
(Basel). 9:1952018. View Article : Google Scholar
|
23
|
Maddalena F, Condelli V, Matassa DS,
Pacelli C, Scrima R, Lettini G, Li Bergolis V, Pietrafesa M, Crispo
F, Piscazzi A, et al: TRAP1 enhances Warburg metabolism through
modulation of PFK1 expression/activity and favors resistance to
EGFR inhibitors in human colorectal carcinomas. Mol Oncol.
14:3030–3047. 2020. View Article : Google Scholar : PubMed/NCBI
|
24
|
Sciacovelli M, Guzzo G, Morello V, Frezza
C, Zheng L, Nannini N, Calabrese F, Laudiero G, Esposito F,
Landriscina M, et al: The mitochondrial chaperone TRAP1 promotes
neoplastic growth by inhibiting succinate dehydrogenase. Cell
Metab. 17:988–999. 2013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Yoshida S, Tsutsumi S, Muhlebach G,
Sourbier C, Lee MJ, Lee S, Vartholomaiou E, Tatokoro M, Beebe K,
Miyajima N, et al: Molecular chaperone TRAP1 regulates a metabolic
switch between mitochondrial respiration and aerobic glycolysis.
Proc Natl Acad Sci USA. 110:E1604–E1612. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
27
|
Landriscina M, Laudiero G, Maddalena F,
Amoroso MR, Piscazzi A, Cozzolino F, Monti M, Garbi C, Fersini A,
Pucci P and Esposito F: Mitochondrial chaperone Trap1 and the
calcium binding protein Sorcin interact and protect cells against
apoptosis induced by antiblastic agents. Cancer Res. 70:6577–6586.
2010. View Article : Google Scholar : PubMed/NCBI
|
28
|
R Core Team: R: A language and environment
for statistical computing. R Foundation for Statistical Computing;
Vienna: 2019, https://www.R-project.org/.
|
29
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zito A, Lualdi M, Granata P, Cocciadiferro
D, Novelli A, Alberio T, Casalone R and Fasano M: Gene set
enrichment analysis of interaction networks weighted by node
centrality. Front Genet. 12:5776232021. View Article : Google Scholar : PubMed/NCBI
|
31
|
Liberzon A, Birger C, Thorvaldsdóttir H,
Ghandi M, Mesirov JP and Tamayo P: The molecular signatures
database (MSigDB) hallmark gene set collection. Cell Syst.
1:417–425. 2015. View Article : Google Scholar
|
32
|
Bartha Á and Győrffy B: http://TNMplot.comurisimpleTNMplot.com: A web tool
for the comparison of gene expression in normal, tumor and
metastatic tissues. Int J Mol Sci. 22:26222021. View Article : Google Scholar
|
33
|
Grandjean G, de Jong PR, James B, Koh MY,
Lemos R, Kingston J, Aleshin A, Bankston LA, Miller CP, Cho EJ, et
al: Definition of a novel feed-forward mechanism for
glycolysis-HIF1α signaling in hypoxic tumors highlights aldolase A
as a therapeutic target. Cancer Res. 76:4259–4269. 2016. View Article : Google Scholar : PubMed/NCBI
|
34
|
Xie H and Simon MC: Oxygen availability
and metabolic reprogramming in cancer. J Biol Chem.
292:16825–16832. 2017. View Article : Google Scholar : PubMed/NCBI
|
35
|
Nowak N, Kulma A and Gutowicz J:
Up-regulation of key glycolysis proteins in cancer development.
Open Life Sci. 13:569–581. 2018. View Article : Google Scholar : PubMed/NCBI
|
36
|
Hao X, Ren Y, Feng M, Wang Q and Wang Y:
Metabolic reprogramming due to hypoxia in pancreatic cancer:
Implications for tumor formation, immunity, and more. Biomed
Pharmacother. 141:1117982021. View Article : Google Scholar : PubMed/NCBI
|
37
|
Silva-Almeida C, Ewart MA and Wilde C: 3D
gastrointestinal models and organoids to study metabolism in human
colon cancer. Semin Cell Dev Biol. 98:98–104. 2020. View Article : Google Scholar
|
38
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
|
40
|
Kuipers EJ, Grady WM, Lieberman D,
Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T:
Colorectal cancer. Nat Rev Dis Primers. 1:150652015. View Article : Google Scholar : PubMed/NCBI
|
41
|
Luengo A, Gui DY and Vander Heiden MG:
Targeting metabolism for cancer therapy. Cell Chem Biol.
24:1161–1180. 2017. View Article : Google Scholar : PubMed/NCBI
|
42
|
Li J, Eu JQ, Kong LR, Wang L, Lim YC, Goh
BC and Wong ALA: Targeting metabolism in cancer cells and the
tumour microenvironment for cancer therapy. Molecules. 25:48312020.
View Article : Google Scholar :
|
43
|
Galluzzi L, Kepp O, Vander Heiden MG and
Kroemer G: Metabolic targets for cancer therapy. Nat Rev Drug
Discov. 12:829–846. 2013. View Article : Google Scholar : PubMed/NCBI
|
44
|
Shah AN, Alam MM, Cao T and Zhang L: The
role of ribosomes in mediating hypoxia response and tolerance in
Eukaryotes. Nova Science Publishers Inc; ISBN:
978-1-62417-698-22013
|
45
|
Staudacher JJ, Naarmann-de Vries IS,
Ujvari SJ, Klinger B, Kasim M, Benko E, Ostareck-Lederer A,
Ostareck DH, Bondke Persson A, Lorenzen S, et al: Hypoxia-induced
gene expression results from selective mRNA partitioning to the
endoplasmic reticulum. Nucleic Acids Res. 43:3219–3236. 2015.
View Article : Google Scholar : PubMed/NCBI
|
46
|
Ivanova IG, Park CV and Kenneth NS:
Translating the hypoxic response-the role of HIF protein
translation in the cellular response to low oxygen. Cells.
8:1142019. View Article : Google Scholar
|
47
|
Chee NT, Lohse I and Brothers SP:
mRNA-to-protein translation in hypoxia. Mol Cancer. 18:492019.
View Article : Google Scholar : PubMed/NCBI
|
48
|
Sanchez-Martin C, Serapian SA, Colombo G
and Rasola A: Dynamically shaping chaperones. allosteric modulators
of HSP90 family as regulatory tools of cell metabolism in
neoplastic progression. Front Oncol. 10:11772020. View Article : Google Scholar : PubMed/NCBI
|
49
|
Costantino E, Maddalena F, Calise S,
Piscazzi A, Tirino V, Fersini A, Ambrosi A, Neri V, Esposito F and
Landriscina M: TRAP1, a novel mitochondrial chaperone responsible
for multi-drug resistance and protection from apoptotis in human
colorectal carcinoma cells. Cancer Lett. 279:39–46. 2009.
View Article : Google Scholar : PubMed/NCBI
|
50
|
Van de Wetering M, Francies HE, Francis
JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J,
Taylor-Weiner A, Kester L, et al: Prospective derivation of a
living organoid biobank of colorectal cancer patients. Cell.
161:933–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
51
|
Sachs N, de Ligt J, Kopper O, Gogola E,
Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H,
et al: A living biobank of breast cancer organoids captures disease
heterogeneity. Cell. 172:373–386.e10. 2018. View Article : Google Scholar
|
52
|
Yan HHN, Siu HC, Law S, Ho SL, Yue SSK,
Tsui WY, Chan D, Chan AS, Ma S, Lam KO, et al: A comprehensive
human gastric cancer organoid biobank captures tumor subtype
heterogeneity and enables therapeutic screening. Cell Stem Cell.
23:882–897.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
53
|
Aggarwal V, Miranda O, Johnston PA and
Sant S: Three dimensional engineered models to study hypoxia
biology in breast cancer. Cancer Lett. 490:124–142. 2020.
View Article : Google Scholar : PubMed/NCBI
|
54
|
Qiu GZ, Jin MZ, Dai JX, Sun W, Feng JH and
Jin WL: Reprogramming of the tumor in the hypoxic niche: The
emerging concept and associated therapeutic strategies. Trends
Pharmacol Sci. 38:669–686. 2017. View Article : Google Scholar : PubMed/NCBI
|
55
|
Marhold M, Tomasich E, El-Gazzar A, Heller
G, Spittler A, Horvat R, Krainer M and Horak P: HIF1α regulates
mTOR signaling and viability of prostate cancer stem cells. Mol
Cancer Res. 13:556–564. 2015. View Article : Google Scholar
|
56
|
Tan VP and Miyamoto S: Nutrient-sensing
mTORC1: Integration of metabolic and autophagic signals. J Mol Cell
Cardiol. 95:31–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
57
|
Chun Y and Kim J: AMPK-mTOR signaling and
cellular adaptations in hypoxia. Int J Mol Sci. 22:97652021.
View Article : Google Scholar : PubMed/NCBI
|
58
|
Melick CH, Meng D and Jewell JL: A-kinase
anchoring protein 8L interacts with mTORC1 and promotes cell
growth. J Biol Chem. 295:8096–8105. 2020. View Article : Google Scholar : PubMed/NCBI
|
59
|
Amin AG, Jeong SW, Gillick JL, Sursal T,
Murali R, Gandhi CD and Jhanwar-Uniyal M: Targeting the mTOR
pathway using novel ATP-competitive inhibitors, Torin1, Torin2 and
XL388, in the treatment of glioblastoma. Int J Oncol. 59:832021.
View Article : Google Scholar :
|
60
|
Morita M, Gravel SP, Hulea L, Larsson O,
Pollak M, St-Pierre J and Topisirovic I: mTOR coordinates protein
synthesis, mitochondrial activity and proliferation. Cell Cycle.
14:473–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
61
|
Hannan KM, Sanij E, Hein N, Hannan RD and
Pearson RB: Signaling to the ribosome in cancer-it is more than
just mTORC1. IUBMB Life. 63:79–85. 2011. View Article : Google Scholar : PubMed/NCBI
|
62
|
Iadevaia V, Liu R and Proud CG: mTORC1
signaling controls multiple steps in ribosome biogenesis. Semin
Cell Dev Biol. 36:113–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
63
|
Tee AR: The target of rapamycin and
mechanisms of cell growth. Int J Mol Sci. 19:8802018. View Article : Google Scholar :
|
64
|
Gentilella A, Kozma SC and Thomas G: A
liaison between mTOR signaling, ribosome biogenesis and cancer.
Biochim Biophys Acta. 1849:812–820. 2015. View Article : Google Scholar : PubMed/NCBI
|
65
|
Valvezan AJ, Turner M, Belaid A, Lam HC,
Miller SK, McNamara MC, Baglini C, Housden BE, Perrimon N,
Kwiatkowski DJ, et al: mTORC1 couples nucleotide synthesis to
nucleotide demand resulting in a targetable metabolic
vulnerability. Cancer Cell. 32:624–638.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
66
|
Pelletier J, Thomas G and Volarević S:
Ribosome biogenesis in cancer: New players and therapeutic avenues.
Nat Rev Cancer. 18:51–63. 2018. View Article : Google Scholar
|
67
|
Chaillou T, Kirby TJ and McCarthy JJ:
Ribosome biogenesis: Emerging evidence for a central role in the
regulation of skeletal muscle mass. J Cell Physiol. 229:1584–1594.
2014. View Article : Google Scholar : PubMed/NCBI
|
68
|
Chen L, Xu B, Liu L, Liu C, Luo Y, Chen X,
Barzegar M, Chung J and Huang S: Both mTORC1 and mTORC2 are
involved in the regulation of cell adhesion. Oncotarget.
6:7136–7150. 2015. View Article : Google Scholar : PubMed/NCBI
|
69
|
Rad E, Murray JT and Tee AR: Oncogenic
signalling through mechanistic target of rapamycin (mTOR): A driver
of metabolic transformation and cancer progression. Cancers
(Basel). 10:52018. View Article : Google Scholar
|
70
|
Yeh HS and Yong J: mTOR-coordinated
post-transcriptional gene regulations: From fundamental to
pathogenic insights. J Lipid Atheroscler. 9:8–22. 2020. View Article : Google Scholar : PubMed/NCBI
|
71
|
Matassa DS, Amoroso MR, Agliarulo I,
Maddalena F, Sisinni L, Paladino S, Romano S, Romano MF, Sagar V,
Loreni F, et al: Translational control in the stress adaptive
response of cancer cells: A novel role for the heat shock protein
TRAP1. Cell Death Dis. 4:e8512013. View Article : Google Scholar : PubMed/NCBI
|
72
|
Sisinni L, Maddalena F, Lettini G,
Condelli V, Matassa DS, Esposito F and Landriscina M: TRAP1 role in
endoplasmic reticulum stress protection favors resistance to
anthracyclins in breast carcinoma cells. Int J Oncol. 44:573–582.
2014. View Article : Google Scholar
|
73
|
Amoroso MR, Matassa DS, Laudiero G,
Egorova AV, Polishchuk RS, Maddalena F, Piscazzi A, Paladino S,
Sarnataro D, Garbi C, et al: TRAP1 and the proteasome regulatory
particle TBP7/Rpt3 interact in the endoplasmic reticulum and
control cellular ubiquitination of specific mitochondrial proteins.
Cell Death Differ. 19:592–604. 2012. View Article : Google Scholar :
|
74
|
Matassa DS, Agliarulo I, Amoroso MR,
Maddalena F, Sepe L, Ferrari MC, Sagar V, D'Amico S, Loreni F,
Paolella G, et al: TRAP1-dependent regulation of p70S6K is involved
in the attenuation of protein synthesis and cell migration:
Relevance in human colorectal tumors. Mol Oncol. 8:1482–1494. 2014.
View Article : Google Scholar : PubMed/NCBI
|
75
|
Delprato A, Al Kadri Y, Pérébaskine N,
Monfoulet C, Henry Y, Henras AK and Fribourg S: Crucial role of the
Rcl1p-Bms1p interaction for yeast pre-ribosomal RNA processing.
Nucleic Acids Res. 42:10161–10172. 2014. View Article : Google Scholar : PubMed/NCBI
|
76
|
Kharde S, Calviño FR, Gumiero A, Wild K
and Sinning I: The structure of Rpf2-Rrs1 explains its role in
ribosome biogenesis. Nucleic Acids Res. 43:7083–7095. 2015.
View Article : Google Scholar : PubMed/NCBI
|
77
|
Turowski TW and Tollervey D:
Cotranscriptional events in eukaryotic ribosome synthesis. Wiley
Interdiscip Rev RNA. 6:129–139. 2015. View Article : Google Scholar
|
78
|
Wang Y, Zhu Q, Huang L, Zhu Y, Chen J,
Peng J and Lo LJ: Interaction between Bms1 and Rcl1, two ribosome
biogenesis factors, is evolutionally conserved in zebrafish and
human. J Genet Genomics. 43:467–469. 2016. View Article : Google Scholar : PubMed/NCBI
|
79
|
Kornprobst M, Turk M, Kellner N, Cheng J,
Flemming D, Koš-Braun I, Koš M, Thoms M, Berninghausen O, Beckmann
R and Hurt E: Architecture of the 90S pre-ribosome: A structural
view on the birth of the eukaryotic ribosome. Cell. 166:380–393.
2016. View Article : Google Scholar : PubMed/NCBI
|
80
|
Sun Q, Zhu X, Qi J, An W, Lan P, Tan D,
Chen R, Wang B, Zheng S, Zhang C, et al: Correction: Molecular
architecture of the 90S small subunit pre-ribosome. Elife.
6:e298762017. View Article : Google Scholar : PubMed/NCBI
|
81
|
Chaker-Margot M, Barandun J, Hunziker M
and Klinge S: Architecture of the yeast small subunit processome.
Science. 355:eaal18802017. View Article : Google Scholar
|
82
|
Boissier F, Schmidt CM, Linnemann J,
Fribourg S and Perez-Fernandez J: Pwp2 mediates UTP-B assembly via
two structurally independent domains. Sci Rep. 7:31692017.
View Article : Google Scholar : PubMed/NCBI
|
83
|
Zhao S, Chen Y, Chen F, Huang D, Shi H, Lo
LJ, Chen J and Peng J: Sas10 controls ribosome biogenesis by
stabilizing Mpp10 and delivering the Mpp10-Imp3-Imp4 complex to
nucleolus. Nucleic Acids Res. 47:2996–3012. 2019. View Article : Google Scholar : PubMed/NCBI
|
84
|
Scaiola A, Peña C, Melanie Weisser M,
Böhringer D, Leibundgut M, Klingauf-Nerurkar P, Gerhardy S, Panse
VG and Ban N: Structure of a eukaryotic cytoplasmic pre-40S
ribosomal subunit. EMBO J. 37:e984992018. View Article : Google Scholar : PubMed/NCBI
|
85
|
Sá-Moura B, Kornprobst M, Kharde S, Ahmed
YL, Stier G, Kunze R, Sinning I and Hurt E: Correction: Mpp10
represents a platform for the interaction of multiple factors
within the 90S pre-ribosome. PLoS One. 15:e02349322020. View Article : Google Scholar
|